Table 1.
Baseline characteristics by dosage and treatment arm
| Characteristic | 0.05 mg/d | 0.15 mg/d | 0.5 mg/d | 1.5 mg/d | 5.0 mg/d | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| P/R (N = 43) |
R/P (N = 44) |
P/R (N = 44) |
R/P (N = 44) |
P/R (N = 41) |
R/P (N = 44) |
P/R (N = 44) |
R/P (N = 44) |
P/R (N = 44) |
R/P (N = 43) |
|
| Mean (± SD) of baseline characteristic | ||||||||||
| Age, years | 48.1 ± 7.8 | 50.4 ± 7.4 | 46.8 ± 8.6 | 48.2 ± 8.0 | 48.8 ± 7.2 | 49.7 ± 7.5 | 49.0 ± 6.7 | 48.5 ± 8.5 | 49.7 ± 7.9 | 44.9 ± 8.4 |
| BMI, kg/m2 | 27.1 ± 2.7 | 27.6 ± 2.3 | 26.4 ± 2.7 | 26.9 ± 2.2 | 26.3 ± 2.7 | 27.0 ± 2.5 | 25.9 ± 3.0 | 26.9 ± 2.4 | 25.8 ± 2.5 | 26.7 ± 2.7 |
| Pulse rate, beats/min | 77.0 ± 10.8 | 77.6 ± 10.3 | 75.8 ± 12.8 | 74.4 ± 9.8 | 75.2 ± 11.0 | 76.8 ± 12.3 | 74.2 ± 11.8 | 80.5 ± 11.5 | 75.8 ± 13.0 | 77.3 ± 10.0 |
| Systolic BP, mm Hg | ||||||||||
| Office | 148.7 ± 7.3 | 150.9 ± 7.4 | 148.0 ± 5.8 | 150.5 ± 8.4 | 150.4 ± 7.6 | 152.5 ± 8.7 | 150.8 ± 7.6 | 151.1 ± 7.8 | 150.6 ± 6.7 | 149.4 ± 7.2 |
| 24-h ambulatory* | 136.8 ± 9.5 | 137.3 ± 11.3 | 135.3 ± 10.4 | 134.9 ± 10.9 | 140.9 ± 11.0 | 137.4 ± 9.6 | 138.1 ± 11.2 | 137.8 ± 11.8 | 138.6 ± 11.4 | 136.2 ± 11.7 |
| Daytime* | 144.4 ± 9.9 | 143.7 ± 12.5 | 141.8 ± 10.4 | 142.3 ± 12.3 | 147.1 ± 12.7 | 142.9 ± 10.1 | 145.0 ± 13.6 | 144.5 ± 12.5 | 145.2 ± 12.6 | 142.2 ± 12.7 |
| Night-time* | 122.2 ± 11.9 | 123.5 ± 13.8 | 122.5 ± 14.8 | 119.9 ± 11.3 | 126.4 ± 12.2 | 125.6 ± 12.6 | 125.7 ± 11.7 | 123.5 ± 14.7 | 125.5 ± 13.0 | 122.8 ± 15.4 |
| Diastolic BP, mm Hg | ||||||||||
| Office | 92.1 ± 7.6 | 93.0 ± 7.0 | 91.9 ± 7.2 | 92.4 ± 7.2 | 92.3 ± 6.9 | 95.9 ± 7.2 | 92.0 ± 7.9 | 94.2 ± 8.2 | 92.8 ± 6.4 | 93.9 ± 6.5 |
| 24-h ambulatory* | 85.5 ± 7.9 | 84.1 ± 7.2 | 84.5 ± 7.6 | 84.2 ± 8.4 | 88.1 ± 9.4 | 87.6 ± 8.8 | 86.5 ± 7.3 | 85.6 ± 8.4 | 86.9 ± 7.0 | 85.0 ± 9.0 |
| Daytime* | 91.6 ± 8.2 | 89.7 ± 8.8 | 90.2 ± 7.5 | 90.2 ± 9.5 | 93.2 ± 10.9 | 92.3 ± 9.1 | 91.5 ± 8.8 | 91.0 ± 8.8 | 92.5 ± 8.3 | 89.6 ± 10.0 |
| Night-time* | 73.4 ± 9.7 | 72.7 ± 8.4 | 74.3 ± 10.8 | 72.3 ± 7.8 | 77.1 ± 9.5 | 78.4 ± 10.8 | 77.1 ± 8.6 | 74.7 ± 11.0 | 76.6 ± 7.7 | 74.2 ± 10.5 |
| Number (%) with baseline characteristic | ||||||||||
| Women | 20 (46.5) | 18 (40.9) | 21 (47.7) | 15 (34.1) | 12 (29.3) | 14 (31.8) | 21 (47.7) | 16 (36.4) | 22 (50.0) | 18 (41.9) |
| Caucasian | 43 (100) | 44 (100) | 44 (100) | 44 (100) | 41 (100) | 42 (95.5) | 43 (97.7) | 43 (97.7) | 44 (100) | 43 (100) |
| Previous AH treatment | 14 (32.6) | 14 (31.8) | 22 (50.0) | 20 (45.5) | 18 (43.9) | 24 (54.5) | 23 (52.3) | 22 (50.0) | 18 (40.9) | 18 (41.9) |
| Current smokers | 5 (11.6) | 7 (15.9) | 6 (13.6) | 9 (20.5) | 6 (14.6) | 8 (18.2) | 5 (11.4) | 7 (15.9) | 14 (31.8) | 12 (27.9) |
| Current alcohol intake | 21 (48.8) | 23 (52.3) | 19 (43.2) | 23 (52.3) | 22 (53.7) | 21 (47.7) | 18 (40.9) | 23 (52.3) | 20 (45.5) | 27 (62.8) |
Values are means ± SD or number (percentage) of patients. N indicates the number of patients. Abbreviations: P/R, 5 weeks placebo followed by 5 weeks rostafuroxin; A/R, 5 weeks rostafuroxin followed by 5 weeks placebo; BP, blood pressure; AH, antihypertensive before the run-in period.
*Ambulatory blood pressure recordings were available in 383 patients.